What is Syllable?
Syllable operates at the intersection of artificial intelligence and healthcare services, aiming to streamline patient-provider interactions. The company's core offerings include a voice assistant and a web assistant designed to facilitate clearer communication channels within the healthcare ecosystem. Based in San Jose, California, Syllable's technology addresses critical needs for improved efficiency and patient engagement in healthcare delivery.
How much funding has Syllable raised?
Syllable has raised a total of $81.7M across 3 funding rounds:
Series A
$13.7M
Series B
$28M
Series C
$40M
Series A (2018): $13.7M, investors not publicly disclosed
Series B (2021): $28M led by Oak HC/FT and Section 32
Series C (2022): $40M supported by Oak HC/FT, The TCV, Section 32, and Verily
Key Investors in Syllable
Oak HC/FT
Oak HC/FT is a venture growth-equity fund specializing in Healthcare Information & Services and Financial Services Technology, providing strategic counsel and business plan execution.
Section 32
Section 32 is a venture capital firm focused on investing in cutting-edge technology and supporting visionary entrepreneurs at the forefront of technological advancement.
Verily
Verily Life Sciences, an Alphabet subsidiary, is a healthcare technology company focused on improving health outcomes through data-driven research and digital health solutions.
What's next for Syllable?
The substantial enterprise-level funding Syllable has garnered, particularly the recent strategic investment, positions the company for accelerated growth and market expansion. This capital infusion is expected to fuel further development of its AI-driven communication tools, enhance its operational capabilities, and broaden its reach within the healthcare sector. Syllable's trajectory suggests a focus on scaling its innovative solutions to meet the growing demand for digital health services.
See full Syllable company page
